3,911 reports of this reaction
4.2% of all SUNITINIB MALATE reports
#4 most reported adverse reaction
DISEASE PROGRESSION is the #4 most commonly reported adverse reaction for SUNITINIB MALATE, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 3,911 FDA adverse event reports linking SUNITINIB MALATE to DISEASE PROGRESSION. This represents approximately 4.2% of all 93,209 adverse event reports for this drug.
SUNITINIB MALATE has an overall safety score of 85 out of 100. Patients taking SUNITINIB MALATE who experience disease progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISEASE PROGRESSION is moderately reported among SUNITINIB MALATE users, representing a notable but not dominant share of adverse events.
In addition to disease progression, the following adverse reactions have been reported for SUNITINIB MALATE:
The following drugs have also been linked to disease progression in FDA adverse event reports:
DISEASE PROGRESSION has been reported as an adverse event in 3,911 FDA reports for SUNITINIB MALATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISEASE PROGRESSION accounts for approximately 4.2% of all adverse event reports for SUNITINIB MALATE, making it a notable side effect.
If you experience disease progression while taking SUNITINIB MALATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.